摘要 在有机氟化合物的显着特征中,对分子的溶解性通常能够实现独特的应用。更重要的是,即使在恶劣的条件下,有机氟化合物也可以与一般的化学反应相容。在此背景下,使用有机氟溶剂对苯酚进行烷基化以制备邻烷基苯酚进行了研究。在此,将报告苯酚在有机氟溶剂中的烷基化及其在生物活性萜烯化酚类天然产物肉豆蔻酸 A 和 E 合成中的应用。我们的研究表明,有机氟溶剂可以更好地替代传统的非解离溶剂作为有机反应介质,以抑制不需要的和非选择性的副反应,例如苯酚的邻烷基化反应。图形概要
5-(Tetradecyloxy)-2-furancarboxylic acid and related hypolipidemic fatty acid-like alkyloxyarylcarboxylic acids
作者:Roger A. Parker、Takashi Kariya、J. Martin Grisar、Vladimir Petrow
DOI:10.1021/jm00216a009
日期:1977.6
5-(Tetradecyloxy)-2-furancarboxylic acid (91, RMI 14514) was found to lower blood lipids and to inhibit fatty acid synthesis with minimal effects on liver weight and liver fat content. This fatty acid-like compound represents a new class of hypolipidemic agent; it is effective in rats and monkeys. The compound resulted from discovery of hypolipidemic activity in certain beta-keto esters, postulation
Modular Approach to Reductive C<sub>sp2</sub>–H and C<sub>sp3</sub>–H Silylation of Carboxylic Acid Derivatives through Single-Pot, Sequential Transition Metal Catalysis
modular approach to catalytic reductive Csp2–H and Csp3–H silylation of carboxylic acid derivatives encompassing esters, ketones, and aldehydes. Choice of either an Ir(I)/Rh(I) or Rh(I)/Rh(I) sequence leads to either exhaustive reductive ester or reductiveketone/aldehyde silylation, respectively. Notably, a catalyst-controlled direct formation of doubly reduced silyl ethers is presented, specifically
of plant, fungal, and bacterial origin. In this paper an improved method for the chemical synthesis of differently substituted chromanes is described. Substituted 2H-1-benzopyrans have been synthesized in good to excellent yields (52–81%) by treatment of 3,3-dimethylallyl and propenylbenzene ethers of differently substituted phenols with phenylselenyl chloride.
苯并二氢吡喃核心在自然界中广泛存在,是植物,真菌和细菌来源的许多次级代谢产物的一部分。在本文中,描述了一种化学合成不同取代的苯并二氢吡喃的改良方法。通过用苯基硒烯基氯处理不同取代的苯酚的3,3-二甲基烯丙基和丙烯基苯醚,可以很好地合成优良的产率(52-81%)的2 H -1-苯并吡喃。
SPIROCYCLIC GPR40 MODULATORS
申请人:Brown Sean P.
公开号:US20110190330A1
公开(公告)日:2011-08-04
The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula IA, IB, I′A or I′B:
where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.
The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula IA, IB, I′A or I′B:
where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.